Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: N/A
- Symbol: NYSE:ZBH
- CUSIP: N/A
- Web: www.zimmerbiomet.com/
Capitalization:- Market Cap: $25.95 billion
- Outstanding Shares: 201,644,000
Average Prices:- 50 Day Moving Avg: $127.30
- 200 Day Moving Avg: $120.33
- 52 Week Range: $95.63 - $133.49
P/E:- Trailing P/E Ratio: 52.66
- Foreward P/E Ratio: 13.97
- P/E Growth: 1.58
Sales & Book Value:- Annual Revenue: $7.76 billion
- Price / Sales: 3.34
- Book Value: $49.27 per share
- Price / Book: 2.61
Dividend:- Annual Dividend: $0.96
- Dividend Yield: 0.8%
Profitability:- EBIDTA: $2.81 billion
- Net Margins: 15.14%
- Return on Equity: 12.25%
- Return on Assets: 4.47%
Debt:- Debt-to-Equity Ratio: 1.06%
- Current Ratio: 1.91%
- Quick Ratio: 1.17%
Misc:- Average Volume: 1.48 million shs.
- Beta: 1.21
- Short Ratio: 3.17
Frequently Asked Questions for Zimmer Biomet Holdings (NYSE:ZBH)
What is Zimmer Biomet Holdings' stock symbol?
Zimmer Biomet Holdings trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."
How often does Zimmer Biomet Holdings pay dividends? What is the dividend yield for Zimmer Biomet Holdings?
Zimmer Biomet Holdings announced a quarterly dividend on Tuesday, May 30th. Stockholders of record on Friday, June 23rd will be paid a dividend of $0.24 per share on Friday, July 28th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date is Wednesday, June 21st. View Zimmer Biomet Holdings' Dividend History.
How were Zimmer Biomet Holdings' earnings last quarter?
Zimmer Biomet Holdings Inc (NYSE:ZBH) posted its quarterly earnings data on Thursday, April, 27th. The company reported $2.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.11 by $0.02. The company earned $1.98 billion during the quarter, compared to the consensus estimate of $1.96 billion. Zimmer Biomet Holdings had a return on equity of 12.25% and a net margin of 15.14%. The business's revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.00 EPS. View Zimmer Biomet Holdings' Earnings History.
When will Zimmer Biomet Holdings make its next earnings announcement?
Where is Zimmer Biomet Holdings' stock going? Where will Zimmer Biomet Holdings' stock price be in 2017?
23 equities research analysts have issued 12 month price targets for Zimmer Biomet Holdings' stock. Their forecasts range from $92.00 to $158.00. On average, they expect Zimmer Biomet Holdings' share price to reach $139.57 in the next twelve months. View Analyst Ratings for Zimmer Biomet Holdings.
What are analysts saying about Zimmer Biomet Holdings stock?
Here are some recent quotes from research analysts about Zimmer Biomet Holdings stock:
- 1. According to Zacks Investment Research, "Over the last three months, Zimmer Biomet was trading below the Zacks categorized Medical Product industry on factors like macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations. Situation deteriorated further with the company lowering a disappointing 2017 outlook. According to the company, lower-than-expected manufacturing output of certain legacy Biomet brands during the first quarter 2017 which may lead to declining product availability in the second quarter, required Zimmer Biomet to lower its guidance. However, we are hopeful about the synergy from LDR Holding buyout, which should complement the company’s musculoskeletal offering. Emerging market expansion is another upside." (7/4/2017)
- 2. Canaccord Genuity analysts commented, "SGEN reported 1Q earnings and provided a pipeline update." (4/28/2017)
- 3. Needham & Company LLC analysts commented, "We hosted a dinner and investor meetings with Dan Florin, Senior Vice President and CFO, and Bob Marshall, Treasurer and Vice President of Investor Relations this week in New York City. We think that the discussion was upbeat and highlighted ZBH's progress in addressing its manufacturing challenges, its non-recon business performance, margin opportunities, and cash flow outlook. The meetings reinforced our view that ZBH should be able to drive its revenue growth to sustainable mid-single digit growth with a combination of market growth in recon and above-market growth in its non-recon businesses. We reiterate our Strong Buy rating." (2/17/2017)
- 4. J P Morgan Chase & Co analysts commented, "Zimmer’s re-acceleration continued into 2Q earnings as sales grew 4.5% pro- forma and 2.6% organic excluding an extra selling day. Organic growth came in well above the Street’s call for 1.6% organic growth and buy-side calls for 1.9% (see our recent survey here). The sales beat was broad based with each business performing in-line or better than Street estimates with Knees (+$2M), Hips (+$9M), SET (+$20M), and Dental (+$5M) as the standout performers in the quarter. While gross margins were lower than expected (70bps), this was tempered by in-line operating expense and a better than expected tax rate including benefits from the early adoption of ASU 2016-09 (+$0.01). When factoring in the better than expected top-line, this drove a $0.05 Cash EPS beat. With Zimmer’s turnaround tracking ahead of expectations, we reiterate our Overweight rating on the stock and raise our price target from $134 to $148 (Y/E 17), conservatively valuing the stock at 15x 2018 Cash EPS, a 20% discount to its peers." (7/29/2016)
Who are some of Zimmer Biomet Holdings' key competitors?
Some companies that are related to Zimmer Biomet Holdings include Baxter International (BAX), C.R. Bard (BCR), DENTSPLY SIRONA (XRAY), Align Technology (ALGN), Bio-Rad Laboratories (BIO), Steris Plc (STE), West Pharmaceutical Services (WST), DexCom (DXCM), Hill-Rom Holdings (HRC), VWR Corporation (VWR), NuVasive (NUVA), Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), LivaNova PLC (LIVN), Nevro Corp. (NVRO), Neogen Corporation (NEOG), Haemonetics Corporation (HAE) and Inogen (INGN).
Who are Zimmer Biomet Holdings' key executives?
Zimmer Biomet Holdings' management team includes the folowing people:
- Daniel P. Florin, Interim Chief Executive Officer, Chief Financial Officer, Director
- Robert D. Delps, President, Americas
- Katarzyna Mazur-Hofsaess M.D. Ph.D., President, Europe, Middle East and Africa
- Sang Yi, President, Asia Pacific
- Chad F. Phipps, Senior Vice President, General Counsel, Secretary
- Larry C. Glasscock, Independent Non-Executive Chairman of the Board
- Christopher B. Begley, Independent Director
- Betsy J. Bernard, Independent Director
- Gail Koziara Boudreaux, Independent Director
- Michael Farrell, Independent Director
Who owns Zimmer Biomet Holdings stock?
Zimmer Biomet Holdings' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Longview Partners Guernsey LTD (3.16%), Focused Investors LLC (0.57%), Factory Mutual Insurance Co. (0.26%), Russell Investments Group Ltd. (0.26%), Hexavest Inc. (0.15%) and Bank of Montreal Can (0.09%). Company insiders that own Zimmer Biomet Holdings stock include Blackstone Capital Partners V, Chad F Phipps, Daniel E Williamson, Daniel P Florin, David A Jr Nolan, David C Dvorak, Sang Yi, Stuart G Kleopfer and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet Holdings.
Who sold Zimmer Biomet Holdings stock? Who is selling Zimmer Biomet Holdings stock?
Zimmer Biomet Holdings' stock was sold by a variety of institutional investors in the last quarter, including Focused Investors LLC, Sit Investment Associates Inc., APG Asset Management N.V., Russell Investments Group Ltd., Affinity Investment Advisors LLC, Hexavest Inc., Exxonmobil Investment Management Inc. TX and US Bancorp DE. Company insiders that have sold Zimmer Biomet Holdings stock in the last year include Chad F Phipps, Daniel E Williamson, David A Jr Nolan, David C Dvorak, Sang Yi, Stuart G Kleopfer and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet Holdings.
Who bought Zimmer Biomet Holdings stock? Who is buying Zimmer Biomet Holdings stock?
Zimmer Biomet Holdings' stock was bought by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Ferguson Wellman Capital Management Inc., Bank of Montreal Can, Mn Services Vermogensbeheer B.V., BTIM Corp., National Pension Service, ING Groep NV and Mitsubishi UFJ Asset Management UK Ltd.. View Insider Buying and Selling for Zimmer Biomet Holdings.
How do I buy Zimmer Biomet Holdings stock?
Shares of Zimmer Biomet Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zimmer Biomet Holdings' stock price today?
One share of Zimmer Biomet Holdings stock can currently be purchased for approximately $128.70.
MarketBeat Community Rating for Zimmer Biomet Holdings (NYSE ZBH)MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Zimmer Biomet Holdings (NYSE:ZBH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 5 Hold Ratings, 16 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.74) |
| Consensus Price Target: | $139.57 (8.45% upside) |
Analysts' Ratings History for Zimmer Biomet Holdings (NYSE:ZBH)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/17/2017 | Morgan Stanley | Boost Price Target | Overweight | $137.00 -> $150.00 | Low |  |
| 7/14/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $141.00 | Low | |
| 7/14/2017 | Stifel Nicolaus | Reiterated Rating | Hold | $125.00 | Low | |
| 7/14/2017 | Bank of America Corporation | Reiterated Rating | Buy -> Buy | $158.00 | Medium | |
| 7/14/2017 | Wells Fargo & Company | Reiterated Rating | Market Weight | | High | |
| 7/14/2017 | Royal Bank Of Canada | Reiterated Rating | Outperform | $140.00 | High | |
| 7/14/2017 | Canaccord Genuity | Reiterated Rating | Buy | $141.00 | High | |
| 7/12/2017 | Needham & Company LLC | Reiterated Rating | Strong-Buy | $153.00 | Low | |
| 7/12/2017 | Guggenheim | Upgrade | Neutral -> Buy | $157.00 | Medium | |
| 7/11/2017 | BMO Capital Markets | Reiterated Rating | Buy | $136.00 | Low | |
| 6/30/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $148.00 | Low | |
| 6/29/2017 | Cantor Fitzgerald | Initiated Coverage | Neutral -> Neutral | $137.00 | Low | |
| 6/9/2017 | Citigroup Inc. | Boost Price Target | Neutral | $108.00 -> $130.00 | Low | |
| 5/16/2017 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Sell -> Sell | $92.00 | High | |
| 4/28/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $132.00 | Low | |
| 2/1/2017 | Robert W. Baird | Reiterated Rating | Outperform | $130.00 -> $136.00 | N/A | |
| 1/5/2017 | J P Morgan Chase & Co | Set Price Target | Buy | $134.00 | N/A | |
| 11/8/2016 | Northcoast Research | Downgrade | Buy -> Neutral | | N/A | |
| 11/1/2016 | Leerink Swann | Reiterated Rating | Outperform | $150.00 -> $136.00 | N/A | |
| 9/22/2016 | Argus | Reiterated Rating | Buy | $140.00 | N/A | |
| 8/23/2016 | Barclays PLC | Boost Price Target | Overweight | $140.00 -> $145.00 | N/A | |
| 8/11/2016 | SunTrust Banks, Inc. | Initiated Coverage | Buy | $155.00 | N/A | |
| 7/29/2016 | JMP Securities | Boost Price Target | Market Outperform | $131.00 -> $145.00 | N/A | |
| 5/16/2016 | Sterne Agee CRT | Reiterated Rating | Buy | | N/A | |
| 3/17/2016 | Nomura | Initiated Coverage | Buy | $123.00 | N/A | |
| 1/31/2016 | William Blair | Reiterated Rating | Outperform | | N/A | |
| 1/29/2016 | Northland Securities | Lower Price Target | | $109.00 -> $105.00 | N/A | |
| 10/30/2015 | Brean Capital | Reiterated Rating | Hold | | N/A | |
| 10/9/2015 | Credit Suisse Group | Initiated Coverage | Outperform | $107.00 | N/A | |
| 7/29/2015 | Deutsche Bank AG | Reiterated Rating | Hold | $114.00 | N/A | |
(Data available from 7/26/2015 forward)
Earnings History for Zimmer Biomet Holdings (NYSE:ZBH)Earnings History by Quarter for Zimmer Biomet Holdings (NYSE ZBH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/27/2017 | Q2 2017 | $2.11 | | | | | N/A | |
| 4/27/2017 | Q1 2017 | $2.11 | $2.13 | $1.96 billion | $1.98 billion | View | N/A | |
| 1/31/2017 | Q416 | $2.11 | $2.14 | $1.98 billion | $2.01 billion | View | Listen | |
| 10/31/2016 | Q316 | $1.79 | $1.79 | $950.20 million | $1.83 billion | View | Listen | |
| 7/28/2016 | Q216 | $1.97 | $2.02 | $1.90 billion | $1.93 billion | View | Listen | |
| 4/28/2016 | Q116 | $1.93 | $2.00 | $1.88 billion | $1.90 billion | View | Listen | |
| 1/28/2016 | Q415 | $2.04 | $2.09 | $1.96 billion | $1.98 billion | View | Listen | |
| 10/29/2015 | Q315 | $1.56 | $1.64 | $1.76 billion | $1.76 billion | View | Listen | |
| 4/30/2015 | Q115 | $1.54 | $1.58 | $1.15 billion | $1.13 billion | View | N/A | |
| 1/29/2015 | Q414 | $1.71 | $0.91 | $1.25 billion | $1.22 billion | View | N/A | |
| 10/23/2014 | Q314 | $1.00 | $0.96 | $1.10 billion | $1.11 billion | View | Listen | |
| 7/24/2014 | Q214 | $1.49 | $1.49 | $1.21 billion | $1.18 billion | View | N/A | |
| 4/24/2014 | Q114 | $1.47 | $1.50 | $1.18 billion | $1.16 billion | View | Listen | |
| 1/31/2014 | Q114 | $1.62 | $1.36 | $1.22 billion | $1.24 billion | View | N/A | |
| 10/24/2013 | Q313 | $1.24 | $1.25 | $1.06 billion | $1.07 billion | View | N/A | |
| 7/25/2013 | Q2 2013 | $1.44 | $1.43 | $1.15 billion | $1.17 billion | View | N/A | |
| 4/25/2013 | Q1 2013 | $1.40 | $1.41 | $1.14 billion | $1.14 billion | View | N/A | |
| 1/31/2013 | Q4 2012 | $1.49 | $1.51 | $1.17 billion | $1.18 billion | View | N/A | |
| 10/25/2012 | | $1.13 | $1.15 | | | View | N/A | |
| 7/26/2012 | | $1.32 | $1.34 | | | View | N/A | |
| 4/26/2012 | | $1.30 | $1.30 | | | View | N/A | |
| 1/26/2012 | | $1.34 | $1.36 | | | View | N/A | |
| 10/27/2011 | | $1.03 | $1.04 | | | View | N/A | |
| 7/27/2011 | | $1.19 | $1.21 | | | View | N/A | |
| 4/28/2011 | | $1.12 | $1.19 | | | View | N/A | |
| 1/27/2011 | | $1.19 | $1.21 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Zimmer Biomet Holdings (NYSE:ZBH)2017 EPS Consensus Estimate: $8.54
2018 EPS Consensus Estimate: $9.37
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | $2.10 | $2.14 | $2.11 |
| Q2 2017 | 6 | $2.08 | $2.18 | $2.12 |
| Q3 2017 | 6 | $1.89 | $2.01 | $1.95 |
| Q4 2017 | 6 | $2.32 | $2.41 | $2.36 |
| Q1 2018 | 3 | $2.25 | $2.32 | $2.29 |
| Q2 2018 | 3 | $2.25 | $2.39 | $2.32 |
| Q3 2018 | 2 | $2.12 | $2.18 | $2.15 |
| Q4 2018 | 2 | $2.59 | $2.63 | $2.61 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Zimmer Biomet Holdings (NYSE:ZBH)| Next Dividend: | 7/28/2017 |
| Annual Dividend: | $0.96 |
| Dividend Yield: | 0.75% |
| Dividend Growth: | 0.00% (3 Year Average) |
| Payout Ratio: | 39.67% (Trailing 12 Months of Earnings)
11.28% (Based on This Year's Estimates)
10.42% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Zimmer Biomet Holdings (NYSE ZBH)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/30/2017 | quarterly | $0.24 | 0.81% | 6/21/2017 | 6/23/2017 | 7/28/2017 |
| 3/1/2017 | quarterly | $0.24 | 0.81% | 3/29/2017 | 3/31/2017 | 4/28/2017 |
| 12/19/2016 | quarterly | $0.24 | 0.94% | 12/28/2016 | 12/30/2016 | 1/27/2017 |
| 8/23/2016 | quarterly | $0.24 | 0.74% | 9/21/2016 | 9/23/2016 | 10/28/2016 |
| 5/23/2016 | quarterly | $0.24 | | 6/22/2016 | 6/24/2016 | 7/29/2016 |
| 2/24/2016 | quarterly | $0.24 | 0.99% | 3/29/2016 | 3/31/2016 | 4/29/2016 |
| 12/14/2015 | quarterly | $0.22 | 0.87% | 12/29/2015 | 12/31/2015 | 1/29/2016 |
| 8/24/2015 | quarterly | $0.22 | 0.9% | 9/28/2015 | 9/30/2015 | 10/30/2015 |
| 5/5/2015 | quarterly | $0.22 | 0.8% | 5/13/2015 | 5/15/2015 | 7/14/2015 |
| 2/24/2015 | quarterly | $0.22 | 0.73% | 3/4/2015 | 3/6/2015 | 4/24/2015 |
| 12/15/2014 | quarterly | $0.22 | 0.81% | 12/24/2014 | 12/29/2014 | 1/30/2015 |
| 8/26/2014 | quarterly | $0.22 | 0.87% | 9/24/2014 | 9/26/2014 | 10/31/2014 |
| 5/23/2014 | quarterly | $0.22 | 0.86% | 6/25/2014 | 6/27/2014 | 7/25/2014 |
| 3/5/2014 | quarterly | $0.22 | 0.9% | 3/26/2014 | 3/28/2014 | 4/25/2014 |
| 12/16/2013 | quarterly | $0.20 | 0.88% | 12/24/2013 | 12/27/2013 | 1/31/2014 |
| 9/9/2013 | quarterly | $0.20 | 0.99% | 9/25/2013 | 9/27/2013 | 10/25/2013 |
| 6/14/2013 | quarterly | $0.20 | 1.03% | 6/26/2013 | 6/28/2013 | 7/26/2013 |
| 3/8/2013 | quarterly | $0.20 | 1.06% | 3/26/2013 | 3/29/2013 | 4/26/2013 |
| 12/14/2012 | quarterly | $0.18 | 1.06% | 12/24/2012 | 12/27/2012 | 1/25/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Zimmer Biomet Holdings (NYSE:ZBH)Insider Ownership Percentage: 1.07%
Institutional Ownership Percentage: 84.37%
Insider Trades by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/12/2017 | Sang Yi | Insider | Sell | 17,731 | $124.56 | $2,208,573.36 | |
| 5/5/2017 | Chad F. Phipps | VP | Sell | 6,200 | $116.76 | $723,912.00 | |
| 4/27/2017 | David C Dvorak | Insider | Sell | 87,331 | $116.47 | $10,171,441.57 | |
| 3/20/2017 | David C Dvorak | Insider | Sell | 1,040 | $121.63 | $126,495.20 | |
| 12/2/2016 | David A. Jr. Nolan | Insider | Sell | 5,050 | $101.11 | $510,605.50 | |
| 9/8/2016 | Daniel E Williamson | Insider | Sell | 2,716 | $129.96 | $352,971.36 | |
| 8/23/2016 | Stuart G Kleopfer | Insider | Sell | 3,397 | $129.71 | $440,624.87 | |
| 8/12/2016 | Tony W. Collins | VP | Sell | 1,287 | $129.16 | $166,228.92 | |
| 8/9/2016 | Stuart G Kleopfer | Insider | Sell | 533 | $132.71 | $70,734.43 | |
| 8/1/2016 | David A. Jr. Nolan | Insider | Sell | 25,255 | $130.77 | $3,302,596.35 | |
| 7/11/2016 | Daniel P Florin | CFO | Sell | 15,000 | $124.98 | $1,874,700.00 | |
| 6/14/2016 | Tony W Collins | CAO | Sell | 3,611 | $116.43 | $420,428.73 | |
| 6/9/2016 | Stuart G Kleopfer | Insider | Sell | 11,000 | $119.45 | $1,313,950.00 | |
| 4/14/2016 | Daniel P Florin | CFO | Sell | 10,000 | $114.98 | $1,149,800.00 | |
| 4/12/2016 | Daniel P Florin | CFO | Sell | 12,000 | $110.00 | $1,320,000.00 | |
| 3/21/2016 | David C Dvorak | CEO | Sell | 1,540 | $104.16 | $160,406.40 | |
| 2/10/2016 | Blackstone Capital Partners V | Major Shareholder | Sell | 7,351,708 | $95.91 | $705,102,314.28 | |
| 1/8/2016 | David C. Dvorak | CEO | Sell | 44,661 | $102.46 | $4,575,966.06 | |
| 12/2/2015 | David A. Jr. Nolan | insider | Sell | 3,435 | $102.62 | $352,499.70 | |
| 6/30/2015 | Adam Rudolph Johnson | Insider | Sell | 30,600 | $110.34 | $3,376,404.00 | |
| 6/29/2015 | Daniel E Williamson | Insider | Sell | 16,000 | $110.98 | $1,775,680.00 | |
| 6/29/2015 | Daniel P Florin | CFO | Sell | 5,000 | $107.00 | $535,000.00 | |
| 3/17/2015 | David C Dvorak | CEO | Sell | 1,300 | $115.55 | $150,215.00 | |
| 12/5/2014 | David C Dvorak | CEO | Sell | 48,703 | $115.00 | $5,600,845.00 | |
| 11/28/2014 | Chad F Phipps | VP | Sell | 5,000 | $112.00 | $560,000.00 | |
| 11/3/2014 | Katarzyna Mazur-Hofsaess | Insider | Sell | 28,253 | $110.01 | $3,108,112.53 | |
| 9/9/2014 | Stephen Hong Liang Ooi | Insider | Sell | 40,768 | $102.78 | $4,190,135.04 | |
| 8/26/2014 | James T Crines | CFO | Sell | 40,768 | $101.00 | $4,117,568.00 | |
| 1/8/2014 | Jeffery Mccaulley | Insider | Sell | 21,286 | $96.00 | $2,043,456.00 | |
| 1/7/2014 | Chad Phipps | VP | Sell | 7,000 | $95.00 | $665,000.00 | |
| 12/20/2013 | Jeffery Mccaulley | Insider | Sell | 21,286 | $93.00 | $1,979,598.00 | |
| 12/3/2013 | Jeffery Mccaulley | Insider | Sell | 2,713 | $90.12 | $244,495.56 | |
| 11/15/2013 | Derek Davis | CAO | Sell | 3,500 | $90.20 | $315,700.00 | |
| 11/14/2013 | Chad Phipps | VP | Sell | 7,800 | $90.00 | $702,000.00 | |
| 11/14/2013 | David Dvorak | CEO | Sell | 64,763 | $90.00 | $5,828,670.00 | |
| 11/14/2013 | Jeffery Mccaulley | Insider | Sell | 21,285 | $90.00 | $1,915,650.00 | |
| 9/13/2013 | Katarzyna Mazur-Hofsaess | Insider | Sell | 4,890 | $81.38 | $397,948.20 | |
| 8/1/2013 | James T Crines | CFO | Sell | 46,200 | $84.56 | $3,906,672.00 | |
| 8/1/2013 | Stephen Hong Liang Ooi | Insider | Sell | 38,500 | $84.27 | $3,244,395.00 | |
| 7/29/2013 | Derek M Davis | CAO | Sell | 3,725 | $83.78 | $312,080.50 | |
| 7/29/2013 | Jeffery A Mccaulley | Insider | Sell | 112,255 | $83.40 | $9,362,067.00 | |
| 7/19/2013 | Chad F Phipps | VP | Sell | 6,000 | $83.00 | $498,000.00 | |
| 5/8/2013 | Chad F Phipps | VP | Sell | 5,000 | $77.26 | $386,300.00 | |
| 4/30/2013 | James T Crines | CFO | Sell | 25,000 | $76.08 | $1,902,000.00 | |
| 4/30/2013 | Jeffery A Mccaulley | Insider | Sell | 10,000 | $76.08 | $760,800.00 | |
| 2/4/2013 | Derek M Davis | CAO | Sell | 21,864 | $72.53 | $1,585,795.92 | |
| 2/4/2013 | Jeffery A Mccaulley | Insider | Sell | 12,000 | $73.60 | $883,200.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Zimmer Biomet Holdings (NYSE:ZBH)
Latest Headlines for Zimmer Biomet Holdings (NYSE:ZBH)
| Source: |
|
| Date | Headline |
|---|
 | Zimmer Biomet Holdings, Inc. (ZBH) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - July 24 at 11:32 PM |
 | Jana Partners Cleans Up, Exits Whole Foods Stake
finance.yahoo.com - July 21 at 9:00 AM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:44 AM |
| Cramer explains why CEO departures are not always bad for...
finance.yahoo.com - July 18 at 4:30 AM |
| Zimmer Biomet: Cramer's Top Takeaways
finance.yahoo.com - July 17 at 11:27 PM |
| Cramer explains why CEO departures are not always bad for companies
finance.yahoo.com - July 17 at 6:25 PM |
| Morgan Stanley Increases Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Price Target to $150.00
www.americanbankingnews.com - July 17 at 5:58 PM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given "Hold" Rating at Stifel Nicolaus
www.americanbankingnews.com - July 15 at 10:34 AM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - July 15 at 9:44 AM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 14 at 12:40 PM |
| Zimmer Biomet Holdings, Inc. (ZBH) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - July 14 at 12:32 PM |
| Zimmer Biomet Holdings' (ZBH) "Buy" Rating Reaffirmed at Bank of America Corporation
www.americanbankingnews.com - July 14 at 12:03 PM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Earns Market Weight Rating from Wells Fargo & Company
www.americanbankingnews.com - July 14 at 10:44 AM |
| Royal Bank Of Canada Reaffirms "Outperform" Rating for Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
www.americanbankingnews.com - July 14 at 10:18 AM |
| Q2 2017 EPS Estimates for Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Decreased by Analyst
www.americanbankingnews.com - July 14 at 8:38 AM |
 | Stryker awarded $248.7 million in patent case against Zimmer ... - Nasdaq
www.nasdaq.com - July 14 at 1:37 AM |
| Jana granted regulatory clearance for Zimmer Biomet stake
finance.yahoo.com - July 13 at 8:35 PM |
| Zimmer Biomet Stock Jumps After Jana Said to Have Taken Significant Stake
finance.yahoo.com - July 13 at 3:32 PM |
| Zimmer Biomet's Preliminary Q2 Numbers Solid, CEO Steps Down
www.nasdaq.com - July 13 at 11:32 AM |
| What CEO Departure Means for Zimmer Biomet
finance.yahoo.com - July 13 at 11:32 AM |
| Analysts Applaud Zimmer CEO Departure
finance.yahoo.com - July 13 at 11:32 AM |
| Medtech CEO Hits 'Third Strike,' Steps Down On Q2 Disappointment
finance.yahoo.com - July 13 at 11:32 AM |
| Zimmer Biomet's Preliminary Q2 Numbers Solid, CEO Steps Down
finance.yahoo.com - July 13 at 11:32 AM |
| Stryker awarded $248.7 million in patent case against Zimmer
finance.yahoo.com - July 13 at 11:32 AM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Expected to Post Quarterly Sales of $1.95 Billion
www.americanbankingnews.com - July 13 at 10:02 AM |
| Zimmer Biomet Holdings' (ZBH) "Strong-Buy" Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - July 12 at 3:41 PM |
| Zimmer Biomet CEO Steps Down; Sees Q2 Adj. EPS At Or Near Bottom Of Prior Range
www.nasdaq.com - July 12 at 1:23 AM |
| Analysts Anticipate Zimmer Biomet Holdings, Inc. (ZBH) Will Post Earnings of $2.11 Per Share
www.americanbankingnews.com - July 12 at 12:06 AM |
 | Zimmer Biomet Holdings (ZBH) CEO Steps Down - StreetInsider.com
www.streetinsider.com - July 11 at 8:23 PM |
| Zimmer Biomet Announces Leadership Transition
finance.yahoo.com - July 11 at 8:22 PM |
| Zimmer Biomet Reports Certain Preliminary Second Quarter 2017 Results
finance.yahoo.com - July 11 at 8:22 PM |
| Zimmer Biomet shares slide on CEO departure, outlook
finance.yahoo.com - July 11 at 8:22 PM |
| Q4 2018 EPS Estimates for Zimmer Biomet Holdings, Inc. (ZBH) Raised by Analyst
www.americanbankingnews.com - July 10 at 9:44 AM |
| [$$] Hans Zimmer, Movie Maestro
finance.yahoo.com - July 8 at 8:40 AM |
| Zimmer Biomet Holdings, Inc. to Post Q2 2018 Earnings of $2.25 Per Share, SunTrust Banks Forecasts (NYSE:ZBH)
www.americanbankingnews.com - July 4 at 12:39 PM |
| Zimmer Biomet Holdings, Inc. (ZBH) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - July 4 at 11:42 AM |
| Cantor Fitzgerald Comments on Zimmer Biomet Holdings, Inc.'s FY2017 Earnings (NYSE:ZBH)
www.americanbankingnews.com - July 4 at 7:30 AM |
| Zimmer Biomet Stock Regains Momentum: What’s Driving Growth?
finance.yahoo.com - July 1 at 9:21 AM |
| Zimmer Biomet Expands Portfolio with X-Ray–Based Knee System
finance.yahoo.com - July 1 at 9:21 AM |
| FDA Warning Letter to Zimmer Biomet Resolved, Boosts Confidence
finance.yahoo.com - July 1 at 9:21 AM |
| ETFs with exposure to Zimmer Biomet Holdings, Inc. : June 30, 2017
finance.yahoo.com - July 1 at 9:21 AM |
| Zimmer Biomet Holdings Announces Live Audio Webcast and Conference Call of Second Quarter 2017 Results
finance.yahoo.com - July 1 at 9:21 AM |
| Zimmer Biomet Holdings, Inc. (ZBH) Receives Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - June 30 at 8:02 AM |
| Invacare Corporation (IVC) Ex-Dividend Date Scheduled for June 29, 2017 - Nasdaq
www.nasdaq.com - June 29 at 9:35 PM |
| Zimmer Biomet Holdings, Inc. (ZBH) Earns Neutral Rating from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - June 29 at 6:02 PM |
| Zimmer Biomet (ZBH) Launches X-Ray-Based X-PSI Knee System
finance.yahoo.com - June 29 at 4:30 PM |
| Zimmer Biomet Introduces the World's First CE Marked, X-Ray-Based Patient Specific Instrument System for Total Knee Replacement Surgery
finance.yahoo.com - June 29 at 8:15 AM |
| Zimmer Biomet Holdings, Inc. (ZBH) Ex-Dividend Date Scheduled for June 21, 2017 - Nasdaq
www.nasdaq.com - June 20 at 3:46 PM |
| ETFs with exposure to Zimmer Biomet Holdings, Inc. : June 20, 2017
finance.yahoo.com - June 20 at 3:45 PM |
| Zimmer Biomet Holdings, Inc. :ZBH-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017
finance.yahoo.com - June 20 at 9:28 AM |
Zimmer Biomet Holdings (ZBH) Chart for Wednesday, July, 26, 2017
